Talk:Corcept Therapeutics: Difference between revisions
Content deleted Content added
Whisoseryus (talk | contribs) ←Created page with '{{ WAP assignment | course = User:Uttsinghuajoint2014/Course Page | term = {{{Spring 2014}}} | }}' |
Whisoseryus (talk | contribs) →Notability of the company: new section |
||
| Line 1: | Line 1: | ||
{{ WAP assignment | course = User:Uttsinghuajoint2014/Course Page | term = {{{Spring 2014}}} | }} |
{{ WAP assignment | course = User:Uttsinghuajoint2014/Course Page | term = {{{Spring 2014}}} | }} |
||
== Notability of the company == |
|||
The company's main drug Korlym reached the market in 2012, which focuses on treatment for severe metabolic and psychiatric disorders, and is approved to be prescribed to global patients; this is the first therapy approved by US [[Food and Drug Administration]] (FDA) for patients with endogenous Cushing's syndrome. <ref>http://www.corcept.com/products</ref> |
|||
Revision as of 12:38, 20 February 2014
Notability of the company
The company's main drug Korlym reached the market in 2012, which focuses on treatment for severe metabolic and psychiatric disorders, and is approved to be prescribed to global patients; this is the first therapy approved by US Food and Drug Administration (FDA) for patients with endogenous Cushing's syndrome. [1]